CTNM earnings: real EPS beat/miss history, analyst consensus Buy, P/E -7.55. Updated 2026-07-23.
Contineum Therapeutics (CTNM) Research Hub
Contineum Therapeutics (CTNM) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 14.82 USD (-2.11%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -7.55, market cap 0.55B. This hub links to the full technical, earnings and options research available for CTNM.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 14.82 USD (-2.11%) |
| 52-week range | 11.47 USD – 17.79 USD |
| Trend regime | Range |
| 14-day RSI | 48.7 (Neutral) |
| Trailing P/E | -7.55 |
| Market cap | 0.55B |
| Dividend yield | 0.00% |
Available research for CTNM
Covered Call on CTNM: how it works, illustrative setup around the real 14.82 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CTNM: how it works, illustrative setup around the real 14.82 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CTNM: how it works, illustrative setup around the real 14.82 USD price, max profit/loss, breakeven and when to use it. Educational.
CTNM technical analysis: range, last 14.82 USD, RSI 48.7, 52w range 11.47 USD–17.79 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CTNM in?
Contineum Therapeutics (CTNM) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CTNM in an uptrend or downtrend?
As of 2026-09-11, CTNM is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CTNM's trailing P/E ratio?
CTNM's trailing P/E is -7.55, with a market cap of 0.55B. See the earnings research page for full valuation detail.